Immunogenicity of bnt162b2 mrna covid-19 vaccine in patients with cardiovascular disease

Hiroyuki Naruse, Hiroyasu Ito, Hideo Izawa, Masayoshi Sarai, Junnichi Ishii, Eirin Sakaguchi, Reiko Murakami, Tatsuya Ando, Hidetsugu Fujigaki, Kuniaki Saito

Research output: Contribution to journalArticlepeer-review

Abstract

Concern has been raised about the effectiveness of the coronavirus disease 2019 (COVID-19) vaccine in the population of patients with various comorbidities such as heart disease. We investigated the humoral response to the BNT162b2 mRNA COVID-19 vaccine in patients with cardiovascular disease (CVD). We measured IgG against severe acute respiratory syndrome coronavirus 2 spike receptor-binding domain (RBD−IgG) in 85 CVD patients and 179 healthcare workers (HCWs). Blood samples were collected from patients and HCWs three times: (1) before the first dose of vaccination, (2) two weeks after the first dose of vaccination, and (3) two weeks after the second dose of vaccination. Patients with CVD showed a significantly inferior serological response to the BNT162b2 mRNA COVID-19 vaccine at 14 days after the prime dose compared to HCWs (21% vs. 95%, p < 0.001). Median RBD−IgG titers of patients with CVD at 14 days after the second dose were significantly lower than those of HCWs (137.2 U/mL (80.6–200.4 U/mL) vs. 176.2 U/mL (123.9–260.0 U/mL), p < 0.001). In multivariable analyses, CVD is significantly associated with seropositivity after first vaccination and RBD−IgG titers after second vaccination. CVD patients may have a poor humoral response to the BNT162b2 mRNA COVID-19 vaccine, need to be closely monitored, and require earlier revaccination to ensure stronger immunity and protection against infection.

Original languageEnglish
Article number5498
JournalJournal of Clinical Medicine
Volume10
Issue number23
DOIs
Publication statusPublished - 01-12-2021

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Immunogenicity of bnt162b2 mrna covid-19 vaccine in patients with cardiovascular disease'. Together they form a unique fingerprint.

Cite this